Search company, investor...
Entegrion company logo


Founded Year



Unattributed | Alive

Total Raised


Last Raised

$13.87M | 5 mos ago

About Entegrion

Entegrion is a life sciences development company specializing in technologies that support preserve the function of the human vascular system. The company's technologies are designed to overcome limitations in temperature, storage, safety, and availability of blood-derived products while improving functionality. The company was founded in 2002 and is based in Durham, North Carolina.

Headquarters Location

4819 Emperor Blvd Suite 400

Durham, North Carolina, 27703,

United States


Missing: Entegrion's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Entegrion's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Entegrion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Entegrion is included in 1 Expert Collection, including Medical Devices.


Medical Devices

8,562 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Entegrion Patents

Entegrion has filed 1 patent.

The 3 most popular patent topics include:

  • Hematology
  • Transfusion medicine
  • Blood
patents chart

Application Date

Grant Date


Related Topics




Coagulation system, Blood tests, Coagulopathies, EC 3.4.21, Polysaccharides


Application Date


Grant Date



Related Topics

Coagulation system, Blood tests, Coagulopathies, EC 3.4.21, Polysaccharides



Latest Entegrion News

Entegrion, Inc. Announces the Expansion of Commercial Operations in Europe

Nov 11, 2022

News Provided By Share This Article VCM Analyzer With the accelerated acceptance for the need of point of care viscoelastic coagulation testing worldwide, Entegrion has launched Entegrion Italia S.R.L.. The board and management of Entegrion are extremely excited to offer our users, alliance partners and shareholders the benefits of expanded support by having taken this important corporate initiative” — Christopher Rumana, Chairman of the Board for Entegrion DURHAM, NORTH CAROLINA, USA, November 11, 2022 / / -- Entegrion, Inc., a leading developer of innovative solutions for clinical diagnosis and management of hemostasis, highlighted the launch of Entegrion Italia S.R.L. to support all international commercial businesses including distribution and alliance partnerships. will be the international arm of Entegrion, Inc., allowing for transparent interface to the European Union for all research and commercial activities. Entegrion Italia, will be responsible for both the animal health and human health markets supported by the VCM and VCM Vet product lines. “The board and management of Entegrion are extremely supportive and excited to offer our users, alliance partners and shareholders the benefits of expanded support by having taken this important corporate initiative,” said Dr. Christopher Rumana, Chairman of the Board for Entegrion. “As Entegrion continues to experience growing demand for the VCM and VCM Vet product lines, we look to expand Entegrion Italia to meet the technical, research and commercial needs of our expanding user base.” About VCM and VCM Vet The VCM product line offers discrete, fully automated, whole blood coagulation monitor capable of delivering a viscoelastic tracing of a patient’s hemostatic state within minutes of applying the sample. VCM and VCM Vet provides hemostasis analysis using viscoelastic coagulation testing. Key parameters that describe the rate of clot formation, the strength, and stability of clotting blood are measured using a proprietary mechanical process. The measured parameters are displayed both numerically and graphically in real time as the blood sample begins to clot, reaches maximum clot strength, and then resolves through fibrinolysis. Because the instrument is available at patient side, the fresh blood sample can be introduced directly into the VCM and VCM Vet. The sample is not manipulated with chemistry, and the test begins automatically when the VCM or VCM Vet test cartridge is inserted into the instrument. The viscoelastic results are immediately available for the doctor to view as they are developing. Contact us for more details or a demonstration at or . About Entegrion Entegrion is a life sciences development company that is focused on improving the diagnosis, monitoring, safety and availability of blood component and hemostasis therapy. Based in North Carolina’s Research Triangle Park, its patented technologies are designed to overcome limitations in storage, safety, and availability of blood-derived products while improving their functionality. Many of Entegrion’s advances in biologics and diagnostics are based on close collaborations with leading medical research institutions. Visit for more information. Bert Valada

Entegrion Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Entegrion Rank

Entegrion Frequently Asked Questions (FAQ)

  • When was Entegrion founded?

    Entegrion was founded in 2002.

  • Where is Entegrion's headquarters?

    Entegrion's headquarters is located at 4819 Emperor Blvd, Durham.

  • What is Entegrion's latest funding round?

    Entegrion's latest funding round is Unattributed.

  • How much did Entegrion raise?

    Entegrion raised a total of $31.46M.

  • Who are the investors of Entegrion?

    Investors of Entegrion include BD Ventures and Catalysta Ventures.

  • Who are Entegrion's competitors?

    Competitors of Entegrion include InvivoSciences, HTG Molecular Diagnostics, Biomatrica, Inotek Pharmaceuticals, Trek Diagnostics and 12 more.

Compare Entegrion to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Biocolor Logo

Biocolor offers assay kits (eg Collagen and Elastin) for tissue culture laboratories.


eSionic, formerly Zettacore, enables devices and systems that consume less materials, generate less waste, have longer life, operate with higher reliability, use less energy, integrate seamlessly, operate more efficiently and cost less.


Bioventix is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.


SIRS-Lab with its diagnostic portfolio! VYOO Sepsis Test is a multiplex pcr detection kit to identifiy bacteria and fungi in whole blood! LOOXSTER sample preparation kit concentrates bacterial and fungal DNA! With expert knowledge in molecular diagnostic, critical care medicine, microbiology, assay design and gene expression service!

CAPE Technologies

CAPE Technologies, of South Portland created a practical immunoassay-based test kits for dioxin and dioxin-like PCBs. The kits provide near real time analysis in a simple field lab, at lower cost, with less equipment, and with fewer people, than conventional methods. CAPE's dioxin kit is the only rapid dioxin screening method accepted by the U.S. Environmental Protection Agency (EPA) for solid waste analysis. A third kit is also available for rapid field analysis of total PCBs. CAPE's kits are marketed by distributors in Australia, Japan, Italy, Taiwan, China, and Finland, and directly through its web site to the rest of the world. CAPE Technologies maintains local ties with the University of New England, the University of Southern Maine, and the University of Maine at Orono. Dr. Robert Harrison of Cape Elizabeth is co-founder and president.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.